NORDSIEK, Michael T.,LEVY, Sharon F.,LEE, James H.,KULP, James H.,BALAJI, Kodumudi S.,MENG, Tze-Chiang,WU, Jason J.,BAHM, Valyn S.,BABILON, Robert
申请号：
ES09837849
公开号：
ES2720149T3
申请日:
2009.12.11
申请国别(地区):
ES
年份:
2019
代理人:
摘要：
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
